The Oncology Institute, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TOI research report →
Range $7 – $10
Price Chart
About the company
The Oncology Institute (TOI) is a specialized healthcare provider delivering a full range of medical oncology services throughout the United States. Its comprehensive offerings include direct physician care, integrated on-site infusion and medication dispensing facilities, and advanced clinical trial management. The institute also provides radiation therapy, specialized outpatient programs for stem cell transplants and transfusions, and robust patient support services.
- CEO
- Daniel Virnich
- IPO
- 2020
- Employees
- 641
- HQ
- Cerritos, CA, US
Get TickerSpark's AI analysis on TOI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $512.91M
- P/E
- -10.34
- Fwd P/E
- 171.00
- PEG
- 0.16
- P/S
- 0.49
- P/B
- -8.27
- EV/EBITDA
- -38.07
- Div Yield
- 0.00%
- Gross Margin
- 16.50%
- Op Margin
- -3.26%
- Net Margin
- -5.73%
- ROE
- 150.78%
- ROIC
- -28.31%
Latest fiscal year · YoY change
- Revenue
- $502.73M+27.8%
- Gross Profit
- $76.44M+41.6%
- Op Income
- $-36,083,000
- Net Income
- $-60,606,000+6.3%
- EPS
- $-0.54+23.9%
- OCF Growth
- +7.4%
- FCF Growth
- +8.4%
- 52W High
- $7.05
- 52W Low
- $2.32
- 50D MA
- $5.28
- 200D MA
- $3.86
- Beta
- 0.42
- RSI (14)
- 49
- Avg Volume
- 1.98M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Starling Oncology posted record Q3 revenue, turned in a second straight quarter of positive adjusted EBITDA, and raised full-year guidance while emphasizing strong pharmacy growth and early traction from its new utilization management portal.· November 5, 2026
- Q3 revenue hit a record $169.8 million, up 24.3% year over year, with adjusted EBITDA of $3.4 million.
- Specialty Pharmacy was the main growth engine: revenue rose 44% year over year to $109.3 million and gross margin reached 24.2%.
- Capitated revenue grew about 40% year over year, while MLR improved to 81% from 85.5% in Q2.
- Management said Starling Nexus is live and showing strong early compliance and speed, with over 99.2% compliance on more than 4,000 Florida authorizations and average decision time of 13 hours.
- Full-year guidance was updated higher, including revenue of $650 million to $660 million and adjusted EBITDA of $4 million to $6 million.
Total revenue in Q3 was $169.8 million, up from $136.6 million a year ago, or 24.3% year-over-year growth. Adjusted EBITDA was $3.4 million, versus a $3.5 million loss in Q3 2025 and $0.2 million in Q2 2026. Gross profit was $30.7 million, and consolidated gross margin was 18.1% versus 13.9% last year. Specialty Pharmacy revenue was $109.3 million, up 44% year over year, with gross margin of 24.2%; patient services revenue was $60 million, including capitated revenue of $28.7 million, up 39.5%, and fee-for-service revenue of $31.3 million, down 21%. MLR was 81%, improved from 85.5% in Q2 and 67.8% a year ago. For the full year, management now expects revenue of $650 million to $660 million, including about $110 million of capitated revenue, gross profit of $107 million to $110 million, adjusted EBITDA of $4 million to $6 million, and free cash flow of $5 million to $10 million. They also guided to Q4 adjusted EBITDA of $3 million to $5 million.
Dan Virnich framed the quarter as proof that the company is scaling its delegated care model and pharmacy business while moving toward profitability. He highlighted the launch and early performance of Starling Nexus, the expansion into Oregon as the first delegated capitation contract outside Florida, and the ability to manage oncology costs at scale. His tone was upbeat and confident, while acknowledging that some capitation timing was pushed out for operational reasons beyond Starling’s control.
Rob Carter focused on margin mechanics, cash flow, and balance sheet changes. He said Specialty Pharmacy gross margin was boosted by procurement and utilization management, plus some rebates and favorable drug pricing that he does not expect to repeat, and therefore expects pharmacy gross margin to normalize in the high teens going forward. He also noted cash and cash equivalents of $36.9 million at quarter-end, long-term debt of $72.5 million, $5 million drawn on the $25 million revolver, operating cash flow of $19.9 million for the first nine months, and free cash flow of $10.7 million in Q3 and $20.2 million year to date.
Analysts focused heavily on the reduced capitated revenue outlook and whether the shortfall was purely timing. Management said the change was timing-related and not due to care model or savings issues, and reiterated that they still expect 100% capitated revenue growth in 2027 versus 2026, with full 2027 guidance to come in Q1. Questions also centered on Starling Nexus and e-prescribing; management said the initial target is practices without their own dispensary, participation is voluntary rather than mandated, and the portal is meant to be an incremental growth channel. On Part D risk, management said it is not a current focus, though they could consider it in the future if payer partners asked for it more directly.
The call showed multiple signs of operating leverage: record revenue, second straight quarter of positive adjusted EBITDA, and improved MLR despite growth in capitated lives. Management sounded confident that Nexus is already improving pathway adherence and authorization speed, and they see a large pipeline that exceeds $1 billion of annualized spend across current and new markets. They also said the pharmacy business remains a durable growth driver, with additional upside from e-prescribing and other ancillary services.
The biggest concern raised was the lower near-term capitated revenue outlook, which management attributed to delayed timing rather than a change in demand, but it still leaves investors waiting for confirmation. Specialty Pharmacy margins were unusually strong this quarter, and management explicitly said some of that benefit came from rebates and favorable price moves that may not recur, so margins are expected to normalize in the high teens. There is also uncertainty around the timing of new contract launches and how much of the large pipeline will actually convert in 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 49.4%
- Shares Outstanding
- 99.98M
- Float Shares
- 49.40M
of shares held by institutions
120 13F filers
Buy/sell ratio 7.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 4.75M | ▲ 203.39K |
| Josh Arnold Investment Consultant, LLC | 2.46M | 0 |
| Goldman Sachs Group Inc | 1.74M | ▲ 383.44K |
| Citadel Advisors LLC | 894.10K | ▲ 285.83K |
| Two Sigma Investments, LP | 668.84K | ▲ 361.08K |
| Northern Trust Corp | 591.53K | ▲ 33.08K |
| Fourworld Capital Management LLC | 499.20K | 0 |
| Manatuck Hill Partners, LLC | 450.00K | ▲ 450.00K |
| Bank Of America Corp | 392.00K | ▲ 328.56K |
| Sg Americas Securities, LLC | 263.15K | ▲ 249.05K |
| Cubist Systematic Strategies, LLC | 185.16K | ▲ 150.46K |
| Dauntless Investment Group, LLC | 163.57K | ▼ 298.49K |
Held by 42 ETFs
Biggest fund positions in TOI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 27, 26 | Kaushal Mohit | other | 33,133 |
| Jul 27, 26 | McGeorge Anne | other | 41,165 |
| Jul 27, 26 | Pacala Mark L | other | 30,120 |
| Jul 27, 26 | STOLPER MARK | other | 31,124 |
| Jul 27, 26 | TZOUMAKAS KIMBERLY JO | other | 29,116 |
| Jul 27, 26 | Hively Brad | other | 27,108 |
| Jul 27, 26 | Johnson Karen Marie | other | 31,124 |
| Jul 21, 26 | Chernett Jorey | buy | 18,000 |
| Jul 14, 26 | Podnos Yale | other | 17,974 |
| Jul 14, 26 | Podnos Yale | other | 5,478 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TOI coverage
Recent articles, reports, and earnings notes.
No research on TOI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TOI report →BlackRock Inc. Buys Shares of 4,749,030 The Oncology Institute, Inc. $TOI
defenseworld.net · Sep 3
Head to Head Contrast: RadNet (NASDAQ:RDNT) and Oncology Institute (NASDAQ:TOI)
defenseworld.net · Aug 24
Oncology Institute Q2 Earnings Call Highlights
marketbeat.com · Aug 7
The Oncology Institute Rebrands as Starling Oncology
globenewswire.com · Aug 3
The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call
globenewswire.com · Jul 27
Best Cheap Stocks Under $10 to Buy Now in July
zacks.com · Jul 7
The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
globenewswire.com · Jul 7
2 More Stocks to Buy for the AI Convergence
investorplace.com · Jul 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.